<DOC>
	<DOC>NCT01233544</DOC>
	<brief_summary>This randomized clinical phase III trial is testing the efficacy of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the treatment of colorectal carcinoma liver metastases. Primary end point is local progression free survival.</brief_summary>
	<brief_title>Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases</brief_title>
	<detailed_description>Patients with 1-4 inoperable colorectal liver metastases, no more 4 cm in diameter are randomized to either RFA or SBRT. Primary end point i local progression free survival. Chemotherapy is allowed before and after study treatment.</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adenocarcinoma of the colon or rectum Liver metastases Inoperable (technical or medical) 14 metastases Maximum 40 mm in diameter Suitable for both therapies, RFA and SBRT Uncontrolled extrahepatic disease and uncontrolled primary cancer Liver cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Colorectal carcinoma</keyword>
	<keyword>Liver metastases</keyword>
	<keyword>Stereotactic body radiation therapy</keyword>
	<keyword>Radiofrequency ablation</keyword>
</DOC>